Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901325 · ClinicalTrials.gov registry record · Phase 2
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04901325 is a Phase 2 study of Wound Heal and Skin Diseases that has completed, run by Oregon Health and Science University. The registered enrollment target is 5 participants, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04901325, a Phase 2 study of Wound Heal and Skin Diseases, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
Conditions Studied
Interventions
- DRUG Baricitinib
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04901325
The ClinicalTrials.gov registry entry for NCT04901325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (96% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib is the first listed.
NCT04901325 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT04901325 about?
NCT04901325 is a clinical study titled "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)". An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
What is the current status of trial NCT04901325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-10-03. Estimated completion is 2025-05-07.
What conditions does trial NCT04901325 study?
This clinical trial studies the following conditions: Wound Heal, Skin Diseases, Skin Ulcer, Pyoderma Gangrenosum, Pyoderma.
What interventions are being tested in trial NCT04901325?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT04901325?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04901325 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
COMPLETED · Phase 2
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.